Carmine N. Stengone, CEO and President at Contineum Therapeutics, Inc. (CTNM), sold 2,500 shares at $16.46 ($41K) on 2026-09-08, disclosed to the SEC on 2026-09-08.
Scheduled sale ($41k) by CEO and President under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| CTNM | SELL | 2026-07-01 | $160K | — | Filing → |
| CTNM | SELL | 2026-02-26 | $227K | — | Filing → |
| CTNM | SELL | 2026-02-13 | $6K | — | Filing → |